<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316407</url>
  </required_header>
  <id_info>
    <org_study_id>CRC 0503</org_study_id>
    <nct_id>NCT00316407</nct_id>
  </id_info>
  <brief_title>Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients</brief_title>
  <official_title>Phase I/II Lapatinib Plus Carboplatin and Paclitaxel in Stage III or IV Relapsed Ovarian or Stage IV Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness, safety, tolerability and best
      dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MTD was found in the phase I portion of this study to be oral lapatinib 1000 mg per day
      for each 4 week cycle and paclitaxel 60 mg/m2 weekly x 3 of a 4 week cycle and carboplatin
      AUC 2 weekly x 3 of a 4 week cycle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response (PR or CR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Ovarian Epithelial Cancer Stage III</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib (GW572016)</intervention_name>
    <description>1000 mg po qd</description>
    <other_name>Tykerb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 2 weekly x 3 of 4 week cycle</description>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>60 mg/m2 weekly x 3 of 4 week cycle</description>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed (Stage III or IV) ovarian, primary peritoneal, fallopian tube carcinoma
             patients.

          -  Stage IV metastatic breast cancer patients who have failed no more than four previous
             chemotherapies for Stage IV disease.

          -  Ability to swallow and retain oral medications.

          -  Measurable disease

        Exclusion Criteria:

          -  Treatment with previous weekly carboplatin and paclitaxel.

          -  No prior treatment with erbB targeting therapies such as erlotinib, gefitinib and
             cetuximab.

          -  No concomitant requirement for medication classification as CYP3A4 inducers or
             inhibitors.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saul Rivkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2006</study_first_submitted>
  <study_first_submitted_qc>April 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2006</study_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Saul Rivkin, M.D.</name_title>
    <organization>Swedish Cancer Institute</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

